Inari Medical

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in July 2011 and is headquartered in Irvine, CA.

Earnings data Q1 2020

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inari Medical reports robust Q4 earnings and eyes international expansion

Inari Medical's Q4 2022 earnings call highlighted strong revenue growth, operational challenges, and strategic opportunities for market expansion and product innovation.
The company's focus on patient outcomes, superior product performance, and international growth positions it for continued success in 2023 and beyond.
Efforts to optimize gross margins, manage operating expenses, and drive market adoption present key areas for Inari's future financial performance and profitability.
With a clear revenue guidance for 2023 and a commitment to sustained operating profitability, Inari Medical demonstrates a strategic roadmap for sustainable growth.

Inari Medical reports robust Q1 earnings, eyes sustained profitability

Inari Medical's Q1 earnings call highlighted strong financial performance, growth strategies, and product innovations. Challenges include competitive dynamics and assessing seasonality trends. The company is well-positioned for sustained growth and market expansion.

Inari Medical reports record revenue and eyes Asian market expansion

Inari Medical's Q2 2023 performance reflects robust financial growth, international expansion, and a strategic focus on addressing unmet needs in the CVD market.
With a strong product portfolio, sustained profitability, and market development initiatives, Inari Medical is well-equipped to capitalize on growth opportunities and drive innovation.
Challenges in market entry, product redesign timelines, and regulatory approvals are being navigated as the company aims for sustained growth and market leadership in the medical device sector.

Inari Medical reports robust Q3 earnings, acquires LimFlow for growth

Inari Medical's Q3 performance reflects strong financial growth, operational improvements, and strategic acquisitions driving future prospects.
While challenges like declining margins and delayed profit targets exist, opportunities in new markets, product pricing, and synergies offer avenues for sustained growth.
The LimFlow acquisition positions Inari well in the CLTI market, with a focus on revenue growth, operational efficiency, and market expansion.
Overall, Inari's confidence in its core business and strategic moves like the LimFlow acquisition signal a positive trajectory and growth outlook.

Inari Medical reports record revenue, eyes sustained profitability amid challenges

Inari Medical's Q4 2023 performance showcased strong revenue growth, operational progress, and a strategic focus on market leadership and patient care.
While facing challenges such as regulatory scrutiny and increased operating expenses, the company remains optimistic about revenue growth and sustained profitability.
Opportunities lie in diversified revenue streams, international expansion, and product portfolio enhancements, positioning Inari for continued growth and market leadership.
Overall, Inari Medical's strategic initiatives and financial performance indicate a resilient and growth-oriented trajectory in the medical device industry.

Inari Medical reports record Q1 revenue, raises full-year guidance

Inari Medical's Q1 performance reflects robust revenue growth, strategic investments, and international expansion, positioning the company for sustained profitability and market leadership.
While facing challenges in competition and market dynamics, Inari's strengths in innovation, global performance, and product development offer avenues for growth and differentiation.
The company's focus on operational efficiency, strategic investments, and product enhancements align with opportunities in expanding toolkits, new therapies, and market presence.

Inari Medical reports record revenue, eyes sustained profitability and global expansion

Inari Medical's Q2 2024 performance reflects strong revenue growth but with operating losses, signaling a need for cost management strategies.
The company's strategic strengths lie in sustained profitability projections, successful business integrations, and expansion into key international markets.
Challenges include leadership transition risks, operational hurdles in new markets, and the need to meet high market expectations with upcoming data releases.
Opportunities for Inari include optimizing costs, leveraging growth in China and Japan, capitalizing on new product adoption, and driving further market expansion.

Inari Medical reports record revenue and eyes global expansion

Inari Medical's Q3 performance reflects robust revenue growth and strategic focus on expanding therapies globally.
The company's strengths lie in revised revenue guidance, upcoming profitability, and promising study outcomes.
Challenges include managing expenses, reducing losses, and sustaining high margins amidst market competition.
Opportunities abound in driving growth, capitalizing on new therapies, and expanding market presence internationally.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inari Medical, Inc. operates as a medical device company. The firm develops, manufactures, markets and sells devices for the interventional treatment of venous diseases. Its products include FlowTriever system and ClotTriever system. The company was founded by Brian J. Cox, Paul Lubock and Robert F. Rosenbluth in June 2011 and is headquartered in Irvine, CA.

Atlassian

It's best to keep it simple with high-growth companies that turn a profit.

I'm Buying These 2 Stocks Amid Market Volatility

eXp World Holdings Inc

Upstart Holdings

These fast-growing companies are on sale right now.

3 Top Stocks to Buy for the May Market Crash

Inari Medical, Inc. (NARI) CEO William Hoffman on Q1 2021 Results - Earnings Call Transcript

Shares of Inari Medical (NASDAQ:NARI) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 44.44% over the past year to $0.13, which beat the estimate of $0.05.

Recap: Inari Medical Q1 Earnings

IRVINE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its first quarter ended March 31, 2021.

Inari Medical Reports First Quarter 2021 Financial Results

Inari Medical (NARI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Inari Medical (NARI) This Earnings Season?

Inari Medical has been a huge success story from the get go - its IPO nearly a year ago. I like the business a great deal and wished I paid up a bit more for this quality company at the time, which was a very different time of course.

Inari Medical: Continued Performance

IRVINE, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 8:45 a.m. Eastern Time.

Inari Medical to Present at the 2021 Bank of America Healthcare Conference

IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its financial results for the first quarter of 2021 on Tuesday, May 11, 2021. In conjunction with the release, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

Inari Medical to Announce First Quarter 2021 Financial Results

IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced a new global partnership with Aidoc, the leading provider of enterprise artificial intelligence (“AI”) solutions, to accelerate the adoption and the clinical impact of AI to advance the timely detection and treatment of pulmonary embolism (“PE”).

Inari Medical Announces Global Partnership with Aidoc to Advance the Timely Detection and Treatment of Pulmonary Embolism

IRVINE, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the enrollment of the first high-risk pulmonary embolism (“PE”) patient in the FlowTriever for Acute Massive Pulmonary Embolism study (“FLAME”). One in 20 PE diagnoses is categorized as high-risk and these are associated with a mortality rate of up to 40% at 90 days.

Inari Medical Announces First Patient Enrolled in FLAME Study

Fulgent Genetics

Teladoc

Industry trends could support massive gains for shareholders over the next 10 years.

3 Growing Healthcare Stocks to Buy and Hold for the Next 10 Years

Fiverr

Even if the bullishness fades, the prospects for these companies have never been better.

3 Unstoppable Stocks to Buy in This Bull Market

Chegg

IAC/InterActiveCorp

The economy is poised to rebound. Many mutual funds are betting big on cyclical stocks.

Wells Fargo Discovery Fund Seeks 'Picassos' Among Growth Stocks

If you are following the crowd, you might miss these disruptive companies.

2 Potential 10-Bagger Stocks Cathie Wood and ARK Don't Own Yet

Laureate Education

Spirit Airlines

Zovio

As bond yields finally drop and tech stocks climb, the deep learning algorithms at Q.ai have crunched the data to give you today's best short plays.

Top Stocks To Short Today As Tech Shares Rise

The clot-removing device maker is nearly perfect, and it's priced like it.

Is Inari Medical a Buy?

Shift4 Payments

I'd increase my stakes in two small caps that I already own.

If I Had $5,000, This Is How I'd Invest It

The stock price of Inari Medical Inc (NASDAQ: NARI) has increased by 19.06%. This is why it happened.

NARI Stock Price Increased 19.06%: Why It Happened

Inari Medical, Inc. (NARI) CEO William Hoffman on Q4 2020 Results - Earnings Call Transcript

IRVINE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported financial results for its fourth quarter and full year ended December 31, 2020.

Inari Medical Reports Fourth Quarter and Full Year 2020 Financial Results

Digital Turbine

Community Health Systems

Novavax

Retractable Technologies

Bancorp

Veritone

VirnetX

XBiotech

These are the small-cap stocks with the best value, fastest growth, and most momentum for March 2021.

Top Small-Cap Stocks for March 2021

IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release financial results for the fourth quarter and full year 2020 after market close on Tuesday, March 9, 2021. On the same day, Inari will host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.

News for Inari Medical Stock (NARI)